Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
4571.T
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q4.22
N/A
-1.60
vs -6.25
Q1.23
N/A
-4.44
vs -6.70
Q2.23
N/A
-4.07
vs -4.68
Q3.23
N/A
-2.73
vs -7.97
Q4.23
N/A
-3.69
vs -1.60
Q1.24
N/A
-0.60
vs -4.44
Q2.24
N/A
-2.22
vs -4.07
Q3.24
N/A
-5.14
vs -2.73
Q4.24
N/A
-1.09
vs -3.69
Q1.25
N/A
-3.40
vs -0.60
Sales Growth
YoY
Current
Estimates
Q4.22
-24%
50.1M vs 65.8M
Q1.23
-6%
60.1M vs 63.8M
Q2.23
+189%
58.9M vs 20.4M
Q3.23
-55%
32.2M vs 71.6M
Q4.23
-74%
13.2M vs 50.1M
Q1.24
-48%
31.2M vs 60.1M
Q2.24
-100%
NA vs 58.9M
Q3.24
-78%
7M vs 32.2M
Q4.24
+476%
76M vs 13.2M
Q1.25
-19%
25.4M vs 31.2M
Return on Equity
QoQ
Q2.23
-7%
-0.07
vs -0.07
Q3.23
-5%
-0.05
vs -0.07
Q4.23
-7%
-0.07
vs -0.05
Q1.24
-1%
-0.01
vs -0.07
Q2.24
-5%
-0.05
vs -0.01
Q3.24
-12%
-0.12
vs -0.05
Q4.24
-3%
-0.03
vs -0.12
Q1.25
-9%
-0.09
vs -0.03
Institutionnal Ownership
Relative Strength
4571.T
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics
Forecast
327%2025-Revenue
61%2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
NaN(-100.00%)
Number of analyst
Last analyst upgrade/downgrade
No Data Available
NanoCarrier Co., Ltd. researches, develops, produces, and sells pharmaceuticals using micelle nanoparticle technology primarily for the treatment of cancer in Japan. The company's product pipeline includes VB-111 non-proliferative adenovirus vector, which is in phase III clinical trials for the treatment of ovarian cancer, as well as in phase II clinical trials for treatment of rGBM and colorectal cancer; ENT103 Otolaryngology product that is in phase III clinical trials for the treatment of otitis media; NC-6004 Cisplatin micelle, which is in phase II clinical trials for the treatment of head and neck cancer; NC-6300 Epirubicin micelle that is in phase I clinical trials for the treatment of hemangiosarcoma; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma and RUNX1 (mRNA) for osteoarthritis of the knee that are in preclinical stage. The company was founded in 1996 and is headquartered in Tokyo, Japan.
JPX
Unprofitable
Unprofitable
Relative Strenght
Volume Buzz
-52%
Earning Acce
No
Dist 52w H.
38%Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How 4571.T compares to sector?